Ranquilon
ApprovedSmall molecule
Ranquilon is one of 35 small molecule programs targeting Anxiety Disorder. It is currently in Approved.
2
Indications
2
Total Trials
1
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
36 competitors in Anxiety Disorder
#DrugCompanyPhaseTrials
1Brintellix
TakedaApproved
Cymbalta
Alnylam PharmaceuticalsApproved
Buspar
Bristol-Myers SquibbApproved
Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Inderal
WWyeth-Lederle Vaccines
Approved
Mifeprex
DDanco
Approved
Xanax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Methylphenidate Hydrochloride
TakedaApproved
Ativan
BBausch Health Americas, Inc.
Approved
Lisdexamfetamine Dimesylate
TakedaApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ranquilon. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- VValenta Pharm JSC